蓝莓视频

Professor Mark Thursz has been appointed Director of Imperial College Academic Health Science Centre (AHSC), who is also the Director of the 蓝莓视频 Imperial BRC. He succeeds Professor Jonathan Weber, a leading HIV expert.

Professor Thursz’s new position would strengthen the current relationship between the two 蓝莓视频 initiatives, BRC and AHSC, and better align research, education and clinical care to accelerate the translation of research into superior patient outcomes.

Professor Thursz was appointed as a consultant in Hepatology at St Mary鈥檚 Hospital in 1997 providing treatment for patients with a wide spectrum of liver diseases. He served as clinical lead for Hepatology for six years and established the Operational Delivery Network for viral hepatitis in North West London. He is also internationally renowned for his research on viral hepatitis and alcohol-related liver disease. He led the聽(EASL) from 2011 鈥� 2013 and authored the European guidelines on Alcohol-Related Liver Disease. In 2011, Professor Thursz launched the聽聽(PROLIFCA) programme to address barriers that prevent the control and elimination of viral hepatitis in countries with limited resources. He also runs a translational research programme in alcohol-related liver disease.

Preventing, detecting and treating disease

As Director, Professor Thursz will play a leading role in advancing Imperial College AHSC鈥檚 work in turning the latest scientific discoveries into new ways of preventing, detecting and treating disease in North West London and beyond.

Innovations that the AHSC is developing to transform health outcomes include a聽聽at Imperial College Healthcare NHS Trust and Chelsea and Westminster Hospital NHS Foundation Trust to monitor patients with sepsis which has led to a reduction in deaths and hospital stays;聽聽at Imperial College Healthcare NHS Trust who had a heart attack has led to fewer readmissions to hospital;聽聽given to breasts cancer patients to reduce side effects and improve outcomes;聽聽to diagnose Alzheimer鈥檚 disease and an聽to treat children with peanut allergy.

The AHSC also played a pivotal role in responding to the COVID-19 pandemic. Researchers from Imperial鈥檚 informed national and international governments鈥櫬犅燨ther researchers developed a rapid聽聽for use in hospitals and led clinical trials evaluating聽, which transformed outcomes for the most critically ill patients. Another group led a nationwide surveillance programme to track the prevalence of COVID-19 in the community 鈥撀�.

Professor Mark Thursz, Director of Imperial College AHSC, said: 鈥淭hroughout my career in medicine I have seen how scientific discoveries can be harnessed to find new ways to improve health and save lives.

鈥淚mperial College AHSC does extraordinary work and I am thrilled to be its next Director. There are new global, national and local challenges ahead and problems to help solve. I know the AHSC is more than equipped to meet these challenges and play a leading role in shaping the future of translational medicine.

鈥淚mperial College AHSC is the embodiment of how science can be a force for good for humanity. This was especially highlighted during the COVID-19 pandemic, where we deployed our academic and clinical expertise to meet that difficult moment.

鈥淎s Director I am looking forward to steering the AHSC through its next chapter and building on the relationships with our partners so that we push the boundaries of translational medicine. One particular area I wish to develop is our use of digital resources to address health challenges in North West London.鈥�

Welcoming Professor Thursz to the role, Professor Mark Walport, Chair of Imperial College AHSC Strategic Partnership Board, said: 鈥淚 want to congratulate and welcome Mark to his role as AHSC Director. He has a longstanding record of excellence and through his leadership, he will ensure that the AHSC delivers on its ambitious strategy to improve healthcare for all.

鈥淭he work of the AHSC is truly transformative. From developing more effective cancer diagnosis tests to new treatments to treat a range of long-term lung conditions, it has led the way in showcasing what can be achieved through collaboration and utilising the strengths of our partners and all our talented staff on a shared mission.鈥�

Professor Tim Orchard, chief executive of Imperial College Healthcare NHS Trust, said: 鈥淲e embed research and innovation in all aspects of our care so that we can provide our patients with cutting-edge treatments and access to medical teams who are at the forefront of medical science.

“Professor Thursz has led the 蓝莓视频 Imperial BRC to be the largest in the country, and it is great that he will bring this track record of leadership to the wider AHSC partnership across northwest London. His ongoing dedication to prioritising a translational approach to medical research will further strengthen our joint aim of bringing benefit from research and clinical trials directly to our patients and local communities and addressing the most pressing health concerns.”

Lesley Watts, Chief Executive of Chelsea and Westminster Hospital NHS Foundation Trust, said:

鈥淚 would like to offer my congratulations to Professor Thursz in his new role as Director of the Imperial College AHSC. His extensive experience and expertise will be fundamental in pushing the boundaries of medical innovation and research, and importantly directly impacting patients鈥� lives. We look forward to working together with Professor Thursz to continue this important work.鈥�

Dame Cally Palmer, CEO at The Royal Marsden NHS Foundation Trust, said: 鈥淚 would like to congratulate Professor Thursz on his appointment. His record of achievement is well established, and I have no doubt under his direction the excellent work of the AHSC will continue.

鈥淚mperial College AHSC is instrumental in ensuring we are always looking at new methods and technologies to improve how we provide healthcare.

鈥淭he way we diagnose and treat cancer is constantly evolving and partnership with the AHSC provides us with even greater insight into the possibilities that exist.鈥�

Professor Kristian Helin, Chief Executive of The Institute of Cancer Research, London, said: 鈥淲e鈥檙e grateful to Professor Weber鈥檚 contributions throughout his leadership and I wish to congratulate Professor Thursz 鈥� we look forward to working productively with him as the new Director of the AHSC.鈥�